<DOC>
	<DOCNO>NCT03084380</DOCNO>
	<brief_summary>The goal clinical trial evaluate safety efficacy anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor ( CAR ) -modified T ( CAR-T ) cell treat patient GPC3-positive advanced hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Anti-GPC3 CAR-T Treating GPC3-positive Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Primary Objectives : 1 . To evaluate safety intravenous administration anti-GPC3 CAR-T cell patient HCC lung squamous cell carcinoma 2 . To access safety anti-GPC3 CAR-T cell HCC patient catheter injection Secondary Objectives : 1 . To evaluate efficacy anti-GPC3 CAR-T cell patient advance HCC lung squamous cell carcinoma 2 . To monitor serum cytokine expression level tumor marker AFP , CEA GPC3 3 . To assess persistence peripheral blood intratumoral infiltration anti-GPC3 CAR-T cell</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Expected survive 3 month PS 02 Immunohistochemistry confirm GPC3 positive hepatocellular carcinoma Patients ability receive TACE combine sorafenib WBC＞3.5×1e+9/L , Hb＞90g/L , PLT＞75×1e+9/L HBV DNA copy number le 100/ml ALT≤5ULN , AST≤5ULN , TB≤1.5ULN , ALB≥35g/L Understand test sign informed consent Hepatic encephalopathy , autoimmune disease , uncontrolled active disease hinders participation trial Decompensated liver cirrhosis , liver function Childpugh C grade Portal vein tumor thrombus , arterial portal fistula , hepatic arteriovenous Longterm use immunosuppressive agent organ transplantation Screening indicated target cell transfection rate le 30 % Invasive pulmonary embolism , deep venous thrombosis , major arterial / venous thromboembolic event occur 30 day 30 day prior randomization Subjects active uncontrollable infection require systemic therapy 14 day 14 day prior randomization Pregnant lactating subject In opinion investigator , presence medical history history mental state may increase number subject associate risk factor associate study study drug administration Subjects sign write consent compliance study procedure ; unwilling unable comply study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>